Lapatinib Untruths You've Been Compelled About

8.0 statistical software. 2.9. Ethics The study was approved by the Institutional Review Board of the Mexican Institute for Social Security (IMSS) of the participating hospital (approval number IMSS R-2010-1303-29), anti-PD-1 monoclonal antibody with all subjects providing written informed consent. 3. Results Figure 1 presents the study's flow chart of the patients meeting the inclusion criteria. Of 54 RA patients with a suspicion of ILD, 15 were excluded from the study because they declined to participate (n = 5) or had exclusion criteria for the study (n = 10), whereas, of 59 RA patients without ILD, 17 were excluded because they met one of the exclusion criteria (see Figure 1). Figure 1 Study flow chart. RA: rheumatoid arthritis; RA-ILD: rheumatoid arthritis with interstitial lung disease; PFT: pulmonary function tests; HRCT: high-resolution computed tomography; FVC: forced vital capacity; anti-CCP: anti-cyclic citrullinated peptide ... Table 1 compares the characteristics of patients with RA-ILD (n = 39) versus RA only (n = 42). Patients with RA-ILD had higher scores for DAS28 (3.9 versus 2.5, P Crenolanib ic50 and HAQ-Di (0.8 versus 0.4, P Selleck Lapatinib disease (RA-ILD) and patients with RA without interstitial lung disease (RA only). Figure 2 illustrates a comparison between anti-CCP2 titers in patients with RA only, compared with RA-ILD. Higher anti-CCP2 titers were observed in RA-ILD (77.9 versus 30.2, P